secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-08-03T21:11:51+00:00
Accession:  0001437749-26-025474
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech raises ~$9.3M in public offering of common stock and warrants
-------------------------------------------------------------------------------

- Gross proceeds of ~$9.3M from sale of 12.4M shares and warrants at $0.75 per unit.
- Warrants exercisable at $0.75 for five years; pre-funded warrants at $0.001.
- Proceeds to fund Annamycin clinical development and working capital.
- Lock-up agreements for officers/directors for 60 days; 45-day ban on further equity issuances.
- Placement agent fees: 6.5% to Roth Capital, 1% to Maxim Group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926025474/0001437749-26-025474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926025474/mbrx20260803_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-025474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer